Active Ingredient(s): Enasidenib
FDA Approved: * August 1, 2017
Pharm Company: * CELGENE CORP
Category: Cancer

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Idhifa Overview

Enasidenib (previously AG-221 and CC-90007) is an experimental drug in development for treatment of cancer. It is a small molecule inhibitor of IDH2 (isocitrate dehydrogenase 2). It was developed by Agios Pharmaceuticals and is licensed to Celgene for further development. The FDA granted fast track designation and orphan drug status for acute myeloid leukemia in 2014.[1] It gained FDA approval in August 2017 for acute myeloid leukemia (AML) in patients with specific mutations of the isocitrat...

Read more Idhifa Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source:

Recent Idhifa Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

  • Tablet: 100mg, 50mg
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Idhifa: (2 results)

Sorted by National Drug Code
  • 59572-705 Idhifa 50 mg Oral Tablet, Film Coated by Celgene Corporation
  • 59572-710 Idhifa 100 mg Oral Tablet, Film Coated by Celgene Corporation

Other drugs which contain Enasidenib or a similar ingredient: (1 result)

Note: All times displayed are GMT - 7.

This information has been independently compiled and is for informational purposes only. It is not intended to be a substitute for medical advice from a qualified healthcare professional; nor is it intended to diagnose, treat, cure or prevent any disease. For more details please see the Medical Disclaimer. Site content is Copyright © 2005-2017 and is protected under U.S. and International Copyright laws. All Rights Reserved. This page was last updated on 20 November 2017.

We are committed to your privacy.

Copyright © 2005-2017 All Rights Reserved. MedsChat® and The People's Medicine Community® are registered trademarks of Limelight Innovations L.L.C.